Aadi Bioscience raises $72.5M in PIPE financing to extend cash runway into 2025

Whitehawk Therapeutics, Inc.

PIPE includes 3,373,526 shares at $12.50 and 2,426,493 pre-funded warrants at $12.4999 with $0.0001 exercise price.
Gross proceeds ~$72.5M; expected close Sept. 26, 2022, subject to customary conditions.
Management participated for ~$750,000; led by a life sciences fund with existing investors.
Proceeds to fund PRECISION 1 trial, FYARRO commercial efforts, and general working capital.
Cash runway expected into 2025; preliminary PRECISION 1 data anticipated in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.